PREPARATION OF α -METHYLENE- γ -BUTYROLACTONES WITH DIFLUOROMETHYLENE FUNCTIONALITIES

Hiroshi Fukuda and Tomoya Kitazume*


Department of Bioengineering, Tokyo Institute of Technology, Nagatsuta, Midori-ku, Yokohama 226, Japan

Abstract- 4-(1,1-Difluoro-2-ethoxycarbonyl)methyl- γ -butyrolactone (**1**) was prepared from the Reformatsky-type reaction of *n*-butyl 3-formylpropanoate with ethyl bromodifluoroacetate in Zn-THF system, and compound (**1**) was converted to α -methylene- γ -butyrolactone derivatives with a difluoromethylene unit at γ -position.

In recent years, fluorinated materials have been receiving much attention in various fields such as pharmacology or functionalized materials because of their unique biological and physical properties.^{1,2} Particularly, the difluoromethylene group is preferred due to its ability to act as a hydrogen donor, allowing the possibility to interact with solvents and biological molecules.³ Recently, we have reported the biological activity of chiral 4,4-difluoro-threonine⁴ and 4-difluoromethylene- γ -butyrolactone.⁵ As a continuation of our interest in the synthesis of materials modified with a difluoromethylene unit, which often exhibit unique biological properties such as aggregation pheromone analogues, we examined the synthesis of α -methylene- γ -butyrolactone derivatives with a difluoromethylene unit at 4-position.


RESULTS AND DISCUSSION

To obtain various types of α -methylene- γ -butyrolactone derivatives with a difluoromethylene unit at 4-position, the synthesis of 4-(1,1-difluoro-2-ethoxycarbonyl)methyl- γ -butyrolactone (1) as a key intermediate in this process, was examined as shown in Scheme 1. In this reaction, compounds (1) and (2) were obtained from the reaction of *n*-butyl 3-formylpropanoate prepared from 4-pentenoic acid with ethyl bromodifluoroacetate in Zn-THF system in the ratio (1: 2 =3.4 : 1). After separating both compounds by column chromatography (silica gel, 35% AcOEt-hexane), compound (2) was hydrolyzed by NaOEt-EtOH system, and then converted to compound (1) by the lactonization in the TsOH-benzene system.



Scheme 1. (a) cat. TsOH, *n*-BuOH, reflux. (quant) (b) OsO₄, NalO₄, THF-H₂O (77%) (c) Zn, BrCF₂CO₂Et, THF (51%) (d) cat. NaOEt, EtOH (71%) (e) cat. TsOH, benzene (98%)

For the purpose to prepare aggregation pheromone analogues, we examined the reduction of ester group with sodium borohydride. In general, it is known that the reduction of ester group with sodium borohydride does not proceed. However, the ester group in compound (1) activated with a difluoromethylene unit was reduced to give diol (4) in NaBH₄-EtOH system. Treatment of the diol (4) with *p*-toluenesulfonic acid in benzene gave 4-(2-hydroxy-1,1-difluoroethyl)- γ -butyrolactone (5) in 95% yield. The triflate (6), prepared from alcohol (5), reacted selectively with sodium iodide in acetone to give the compound (7) in good yield . The compound (7) then reacted with AlBN-*n*-Bu₃SnH system to give aggregation pheromone analogue (8) of *Trogoderma glabrum*. Forthermore, the synthesis of 4-(1,1-difluoroethyl)- α -methylene- γ -butyrolactone (9) was acheived by introduction of the methylene group at α -position (Scheme 2). The compound (10) derived from compound (4) was also transformed to compund (11) with *p*-toluenesulfonic acid in benzene, and then a synthesis of 4-(1,1-difluoro-2-hydroxyethyl)- α -methylene- γ -butyrolactone (13) possessing 1,1-difluoro-2-hydroxyethyl group attached to the 4-position of α -methylene- γ -butyrolactone was achieved by introduction of the methylene group at α -position of the methylene group at α -position of the methylene- γ -butyrolactone (13) possessing 1,1-difluoro-2-hydroxyethyl group attached to the 4-position of α -methylene- γ -butyrolactone was achieved by introduction of the methylene group at α -position of the methylene group at α -position (5 the methylene group at α -position



Scheme 2. (a) NaBH₄, EtOH (64%) (b) cat. TsOH, benzene, reflux (95%) (c) Tf₂O, *i*-Pr₂NEt, CH₂Cl₂ (90%) (d) NaI, acetone (quant) (e) cat. AIBN, *n*Bu₃SnH (75%) (f) LDA, CH₂NMe₂⁺ I⁻, Mel (g) TBSCI, imidazole, DMF (quant.) (h) cat. TsOH, benzene (i) LDA, CH₂NMe₂⁺ I⁻, Mel (j) TBAF, THF

EXPERIMENTAL

General : All commercially available reagents were used without further purification. Chemical shifts of ¹H (500 MHz) and ¹³C NMR spectra were recorded in ppm (δ) downfield from the following internal standards (Me₄Si, δ 0.00, or CHCl₃, δ 7.24). The ¹⁹F (470 MHz) NMR spectra were recorded in ppm downfield from external CFCl₃ in CDCl₃ using VXR 500 instrument. Yields quoted are those of the products actually isolated.

n-Butyl 4-pentenoate

The solution of 4-pentenoic acid (0.204 mL, 2.0 mmol) and a catalytic amount of *p*-toluenesulfonic acid in *n*-butanol (2 mL) was stirred at 130 °C. After 1 h of stirring at that temperature, the solvent was removed *in vacuo*. The residual oil was purified by column chromatography (silica gel, 10% AcOEt-hexane) to give *n*-butyl 4-pentenoate (313 mg) in quantitative yield. ¹H NMR (CDCl₃): δ 0.94 (3 H, t, *J=*7.6 Hz), 1.34-1.43 (2 H, m), 1.57-1.64 (2 H, m), 2.34-2.43 (4 H, m), 4.08 (2 H, t, *J=* 6.8 Hz), 4.98-5.09 (2 H, m), 5.78-5.87 (1 H, m); ¹³C NMR (CDCl₃): δ 13.8, 19.3, 29.0, 30.8, 33.7, 64.3, 115.5, 136.8, 173.1. IR (neat): v 1738, 1175 cm⁻¹.

n-Butyl 3-formylpropanoate

Into a solution of *n*-butyl 4-pentenoate (10.9 g, 70 mmol) and a catalytic amount of osumium tetraoxide in tetrahydrofuran-water (2 : 1, 350 mL), sodium metaperiodate (29.9 g, 140 mmol) was added at rt. After 3 h of stirring at rt, the mixture was quenched with water. The organic layer was separated and the aqueous layer was extracted with ether. The combined organic extracts were dried over MgSO₄, and the solvent was removed *in vacuo*. The residual oil was purified by column chromatography (silica gel, 30% AcOEt-hexane) to give *n*-butyl 3-formylpropanoate (8.52 g) in 77% yield.¹H NMR (CDCl₃): δ 0.94 (3 H, t, *J*=7.6 Hz), 1.34-1.42 (2 H, m), 1.58-1.65 (2 H, m), 2.63 (2 H, t, *J*= 6.6 Hz), 2.80 (2 H, td, *J*= 6.4, 0.5 Hz), 4.10 (2 H, t, *J*= 6.6 Hz), 9.82 (1H, m);¹³C NMR (CDCl₃): δ 13.7, 19.1, 26.6, 30.6, 38.6, 64.7, 172.4, 200.2. IR (neat): v 1734, 1179 cm⁻¹.

4-(1,1-Difluoro-2-ethoxycarbonyl)methyl-γ-butyrolactone (**1**)

To a solution of *n*-butyl 4-pentenoate (1.35 g, 8.53 mmol) and zinc (837 mg, 12.8 mmol) in tetrahydrofuran (85 mL), ethyl bromodifluoroacetate (1.42 mL, 11.1 mmol) was added at 0 °C under an argon atmosphere. After 2 h of stirring at that temperature, the mixture was quenched with 1 *N* HCl. The organic layer was separated and the aqueous layer was extracted with ether. The combined organic extracts were dried over MgSO₄. On removal of the solvent, oily materials were purified by column chromatography (silica gel, 35% AcOEthexane) to give 4-(1,1-difluoro-2-ethoxycarbonyl)methyl- γ -butyrolactone (**1**) (910 mg) and dimer (**2**) (610 mg, 1.29 mmol) in 51% and 15% yields, respectively. ¹H NMR (CDCl₃): δ 1.38 (3 H, t, *J*=7.1 Hz), 2.41-2.48 (2 H, m), 2.52-2.60 (1 H, m), 2.63-2.72 (1 H, m), 4.39 (2 H, q,

J=7.1 Hz), 4.92-5.00 (1 H, m);¹³C NMR (CDCl₃): δ 13.9, 20.6 (q, J=1.8 Hz), 26.7 (d, J=1.6 Hz), 63.7, 76.5 (dd, J=32.8, 24.9 Hz), 112.8 (dd, J=257, 251 Hz), 162.0 (dd, J=32.1, 29.7 Hz), 175.5;¹⁹F NMR (CDCl₃): δ -125 (dd, J=273, 16.8 Hz), -117 (dd, J=273, 6.1 Hz);IR (neat): v 1797 cm⁻¹;HRMS calcd for C₈H₁₀O₄F₂ (M)+ 208.0546, found 208.0538.

4,8-Bis{(2-n-butoxycarbonyl)ethyl}-3,3,7,7-tetrafluoro-2,6-dioxo-1,5-dioxocane (**2**) ¹H NMR (CDCl₃): δ 0.96 (6 H, t, *J*=7.3 Hz), 1.34-1.46 (4 H, m), 1.69-1.75 (4 H, m), 2.41-2.49 (4 H, m), 2.52-2.60 (2 H, m), 2.63-2.72 (2 H, m), 4.33 (4 H, t, *J*=6.8 Hz), 4.91-5.00 (2 H, m);¹³C NMR (CDCl₃): δ 13.6, 18.9, 20.6 (q, *J*=1.8 Hz), 26.7 (d, *J*=1.5 Hz), 30.2, 67.4, 76.5 (dd, *J*=33.1, 25.0 Hz), 112.8 (dd, *J*=257, 251 Hz), 162.1 (dd, *J*=32.4, 29.8 Hz), 175.4; ¹⁹F NMR (CDCl₃): δ -125 (dd, *J*=273, 16.8 Hz), -117 (dd, *J*=273, 6.1 Hz); IR (neat): v 1800 cm⁻¹.

Ethyl 2,2-difluoro-5-ethoxycarbonyl-3-hydroxypentanoate (3)

To a solution of 4,8-bis{(2-*n*-butoxycarbonyl)ethyl}-3,3,7,7-tetrafluoro-2,6-dioxo-1,5dioxocane (605 mg, 1.28 mmol), a catalytic amount of sodium ethoxide in ethanol (13 mL) was added at 80 °C under an argon atmosphere. After 2 days of stirring at that temperature, the solvent was removed. The residue was diluted with ether, and then the mixture was quenched with 1 *N* HCl. The organic layer was separated and the aqueous layer was extracted with ether. The combined organic extracts were dried over MgSO₄. On removal of the solvent, oily materials were purified by column chromatography (silica gel, 30% AcOEthexane) to give ethyl 2,2-difluoro-5-ethoxycarbonyl-3-hydroxypentanoate (**3**) (462 mg) in 71% yield.¹H NMR (CDCl₃): δ 1.27 (3 H, t, *J*=7.1 Hz), 1.37 (3 H, t, *J*=7.3 Hz), 1.88-1.98 (1 H, m), 2.01-2.09 (1 H, m), 2.51-2.64 (2 H, m), 3.00 (1 H, *J*=6.6 Hz), 4.07-4.19 (3 H, m), 4.16 (2 H, q, *J*=7.3 Hz), 4.37 (2 H, q, *J*=7.1 Hz);¹³C NMR (CDCl₃): δ 13.9, 14.1, 24.2 (q, *J*=1.9 Hz), 30.1, 61.0, 63.2, 71.0 (t, *J*=24.6 Hz), 114.6 (dd, *J*=256, 252 Hz), 163.6 (dd, *J*=32.8, 30.9 Hz), 174.0;¹⁹F NMR (CDCl₃): δ -124 (dd, *J*=264, 16.8 Hz), -116 (dd, *J*=264, 6.1 Hz); IR (neat): v 3467, 1761, 1735 cm⁻¹.

Ethyl 5,5-difluoro-4,6-dihydroxyhexanoate (4)

Into the flask containing sodium borohydride (1.21 g, 32.1 mmol), a solution of ethyl 2,2difluoro-5-ethoxycarbonyl-3-hydroxypentanoate (8.17 g, 32.1 mmol) in ethanol (160 mL) was added at it under an argon atmosphere. After 30 min of stirring at that temperature, the mixture was quenched with NH₄Cl powder. On removal of the solvent, the residue was diluted with ethyl acetate. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic extracts were dried over MgSO₄. On removal of the solvent, oily materials were purified by column chromatography (silica gel, 65% AcOEt-hexane) to give ethyl 5,5-difluoro-4,6-dihydroxyhexanoate (4) (4.34 g) in 64% yield.¹H NMR (CDCl₃): δ 1.27 (3 H, t, *J*=7.1 Hz), 1.88-1.96 (1 H, m), 2.03-2.10 (1 H, m), 2.44-2.50 (1 H, m), 2.55 (1 H, ddd, *J*=17.1, 7.6, 6.1 Hz), 2.61 (1 H, ddd , *J*=17.1, 7.8, 5.9 Hz), 3.31 (1 H, d, *J*=5.9 Hz), 3.84-4.04 (3 H, m), 4.17 (2 H, q, *J*=7.1 Hz);¹³C NMR (CDCl₃): δ 14.0, 24.3 (t, *J*=3.2 Hz), 30.3, 60.9, 61.6 (dd, *J*=32.9, 28.1 Hz), 70.0 (dd, *J*=29.8, 25.4 Hz), 121.2 (dd, *J*=247, 245 Hz), 174.4;¹⁹F NMR (CDCl₃): δ -126 (dtd, *J*=258, 16.8, 10.7 Hz), -119 (dddd, *J*=258, 18.3, 12.2, 6.1 Hz); IR (neat): 3426, 1715 cm⁻¹; HRMS calcd for C₈H₁₄O₄F₂ (M)⁺ 212.0859, found 212.0874.

4-(2-Hydoxy-1,1-difluoroethyl)-γ-butyrolactone (5)

To a solution of ethyl 5,5-difluoro-4,6-dihydroxyhexanoate (**4**) (5.86 g, 27.6 mmol) in benzene (140 mL), a catalytic amount of *p*-toluenesulfonic acid was added at 90 °C. After 2 h of stirring at 90 °C, the solvent was removed *in vacuo*. Oily materials were purified by column chromatography (silica gel, 65% AcOEt-hexane) to give 4-(2-hydoxy-1,1difluoroethyl)- γ -butyrolactone (**5**) (4.33 g) in 95% yield.¹H NMR (CDCl₃): δ 2.24 (1 H, s), 2.35-2.71 (4 H, m), 3.88-4.04 (2 H, m), 4.86 (1 H, dddd, *J*=21.2, 8.3, 4.4, 2.4 Hz);¹³C NMR (CDCl₃): δ 20.3 (dd, *J*=3.9, 2.1 Hz), 27.2 (d, *J*=1.6 Hz), 61.3 (dd, *J*=34.8, 26.2 Hz), 75.4 (dd, *J*=37.9, 25.2 Hz), 120.0 (dd, *J*=247, 244 Hz), 176.9;¹⁹F NMR (CDCl₃): δ -128 (ddt, *J*=266, 21.4, 7.6 Hz), -120 (dddd, *J*=266, 22.9, 13.7, 3.1 Hz); IR (neat): v 3441, 1790 cm⁻¹; HRMS calcd for C₆H₈O₃F₂ (M)⁺ 166.0441, found 166.0453.

4-{1,1-Difluoro-2-(trifluoromethanesulfonyloxy)ethyl}-γ-butyrolactone (6)

To a solution of 4-(2-hydoxy-1,1-difluoroethyl)-γ-butyrolactone (**5**) (1.0 g, 6.02 mmol) in dichloromethane (30 mL), diisopropylethylamine (1.26 mL, 7.22 mmol) and trifluoromethanesulfonic anhydride (1.21 mL, 7.22 mmol) was added at 0 °C. After 30 min of stirring at 0 °C, the mixture was quenched with water. The organic layer was separated and the

281

aqueous layer was extracted with dichloromethane. The combined organic extracts were dried over MgSO₄. On removal of the solvent, oily materials were purified by column chromatography (silica gel, 35% AcOEt-hexane) to give 4-{1,1-difluoro-2-(trifluoro-methanesulfonyloxy)ethyl}- γ -butyrolactone (**6**) (1.61 g) in 90% yield.¹H NMR (CDCl₃): δ 2.42-2.73 (4 H, m), 4.70-4.81 (3 H, m);¹³C NMR (CDCl₃): δ 20.1 (dd, *J*=3.9, 1.7 Hz), 26.8, 70.5 (dd, *J*=38.7, 26.1 Hz), 74.7 (dd, *J*=37.5, 24.6 Hz), 117.1 (t, *J*= 248 Hz), 118.6 (q, *J*=318 Hz), 175.2;¹⁹F NMR (CDCl₃): δ -128 (ddt, *J*=272, 22.9, 6.1 Hz), -119 (dt, *J*=272, 16.8 Hz), -75.2; IR (neat): v 1802 cm⁻¹.

4-(1,1-Difluoro-2-iodoethyl)-γ-butyrolactone (7)

To a solution of 4-{1,1-difluoro-2-(trifluorometanesulfonyloxy)ethyl}- γ -butyrolactone (**6**) (1.51 g, 5.07 mmol) in acetone (50 mL), sodium iodide (988 mg, 6.59 mmol) was added at rt. After 3 h of stirring at that temperature, the solvent was removed *in vacuo*. The residue was diluted with ether, and the mixture was quenched with water. The organic layer was separated and the aqueous layer was extracted with ether. The combined organic extracts were dried over MgSO₄. On removal of the solvent, oily materials were purified by column chromatography (silica gel, 40% AcOEt-hexane) to give 4-(1,1-difluoro-2-iodoethyl)- γ -butyrolactone (**7**) (1.40 g) in quantitative yield.¹H NMR (CDCl₃): δ 2.32-2.74 (4 H, m), 3.48-3.66 (2 H, m), 4.91 (1 H, ddd, *J*=22.0, 8.3, 0.7 Hz);¹³C NMR (CDCl₃): δ 0.3 (dd, *J*=30.8, 27.2 Hz), 20.9 (dd, *J*=3.7, 1.7 Hz), 26.9 (d, *J*=1.8 Hz), 76.3 (dd, *J*=38.8, 26.6 Hz), 118.2 (dd, *J*=247, 243 Hz), 175.5;¹⁹F NMR (CDCl₃): δ -114 (ddd, *J*=253, 22.9, 6.1 Hz), -120 (dt, *J*=253, 18.3 Hz); IR (neat): v 1790 cm⁻¹; HRMS calcd for C₆H₇O₂F₂I (M)+ 275.9457, found 275.9448.

4-(1,1-Difluoroethyl)-γ-butyrolactone (8)

To a solution of 4-(1,1-difluoro-2-iodoethyl)- γ -butyrolactone (7) (247 mg, 0.895 mmol) and *n*butyltin hydride (0.31 mL, 1.16 mmol) in benzene (10 mL), a catalytic amount of 2,2'azobis(isobutyronitrile) was added at 90 °C. After 30 min of stirring at 90 °C, the mixture was quenched with saturated KF aq. and the precipitate was filtered. The organic layer was separated and the aqueous layer was extracted with ether. The combined organic extracts were dried over MgSO₄. On removal of the solvent, oily materials were purified by column chromatography (silica gel, 35% AcOEt-hexane) to give 4-(1,1-difluoroethyl)- γ -butyrolactone (8) (101 mg) in 75% yield.¹H NMR (CDCl₃): δ 1.72 (3 H, t, *J*=19.0 Hz), 2.30-2.46 (2 H, m), 2.53 (1 H, ddd, *J*=18.1, 10.5, 1.5 Hz), 2.64 (1 H, ddd, *J*=18.1, 9.8, 1.5 Hz), 4.53 (1 H, dddd, *J*=19.3, 8.7, 4.6, 3.2 Hz);¹³C NMR (CDCl₃): δ 20.4 (dd, *J*=26.7, 25.1 Hz), 21.0 (dd, *J*=3.8, 2.4 Hz), 27.2 (d,*J*=1.7 Hz), 79.0 (dd, *J*=37.1, 27.9 Hz), 121.5 (dd, *J*=243, 238 Hz), 176.3;¹⁹F NMR (CDCl₃): δ -111 (dquint, *J*=255, 18.3 Hz), -104 (ddq, *J*=255, 18.3, 3.1 Hz); IR (neat): v 1793 cm⁻¹; HRMS calcd for C₆H₈O₂F₂ (M)⁺ 150.0492, found 150.0479.

4-(1,1-Difluoroethyl)- α -methylene- γ -butyrolactone (9)

To a solution of diisopropylamine (0.377 mL, 2.69 mmol) in tetrahydrofuran (10 mL), n-butyllithium (1.6 M in hexane, 1.68 mL, 2.69 mmol) was added at -78 °C under a nitrogen atmosphere. After 10 min of stirring, 4-(1,1-difluoroethyl)- γ -butyrolactone (8) (308 mg, 2.06 mmol) in tetrahydrofuran (10 mL) was added at -78 °C. After 1 h of stirring, N,Ndimethylmethyleneammonium iodide (575 mg, 3.11 mmol) was added and stirred for 1 h. The solvent was removed and diluted with methanol. Methyl iodide (2 mL) was added to the mixture and the whole was stirred for 24 h. On removal of the solvent, the residue was diluted with dichloromethane and aqueous 5% NaHCO₃ solution was added to the mixture and vigurously stirred. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic extracts were dried over MgSO₄. On removal of the solvent, oily materials were purified by column chromatography (silica gel, 35 % AcOEt-hexane) to give 4-(1,1-difluoroethyl)- α -methylene- γ -butyrolactone (9) (100 mg) in 30 % yield.¹H NMR (CDCl₃): δ 1.73 (3 H, t, *J*=19.0 Hz), 3.04 (1 H, ddt, *J*=18.1, 8.3, 2.9 Hz), 3.10 (1 H, ddt, J=18.1, 4.9, 2.7 Hz), 4.56 (1 H, dddd, J=17.8, 8.3, 5.1, 3.2 Hz), 5.74 (1 H, t, J=2.4 Hz), 6.30 (1 H, t, J=2.4 Hz);¹⁹F NMR (CDCl₂): δ -112 (dquit, J=255, 18.3 Hz), -104 (dtd, J=255, 18.3, 3.1 Hz); IR (neat): v 1778, 1665 cm⁻¹; HRMS calcd for C₇H₈O₂F₂ (M)+ 162.0492, found 162.0485.

Ethyl 6-t-butyldimethylsilyloxy-5,5-difluoro-4-hydroxyhexanoate (10)

To a solution of ethyl 5,5-difluoro-4,6-dihydroxyhexanoate (**4**) (2.12 g, 10.0 mmol) and imidazole (749 mg, 11.0 mmol) in dimethylformamide (10 mL), *t*-butyldimethylsilyl chloride (1.66 g, 11.0 mmol) was added at rt under an argon atmosphere. After the mixture was stirred overnight, the mixture was quenched with aqueous 5% NaHCO₃ solution and diluted with ether. The organic layer was separated and the aqueous layer was extracted with ether.

The combined organic extracts were dried over MgSO₄. On removal of the solvent, oily materials were purified by column chromatography (silica gel, 30% AcOEt-hexane) to give ethyl 6-*t*-butyldimethylsilyloxy-5,5-difluoro-4-hydroxyhexanoate (**10**) (3.23 g) in quantitative yield.¹H NMR (CDCl₃): δ 0.10 (6 H, d, *J*=0.7Hz), 0.90 (9 H, s), 1.26 (3 H, t, *J*=7.1 Hz), 1.86-1.95 (1 H, m), 2.01-2.09 (1 H, m), 2.55 (2 H, td, *J*=7.3, 2.2 Hz), 2.82 (1 H, d, *J*=6.1 Hz), 3.84 (1 H, q, *J*=11.5 Hz), 3.91-4.02 (2 H, m), 4.14 (2 H, q, *J*=7.1 Hz);¹³C NMR (CDCl₃): δ -5.6, 14.1, 18.2, 24.5 (t, *J*=3.2 Hz), 25.7, 30.5, 60.6, 62.8 (dd, *J*=35.4, 30.8 Hz), 70.2 (dd, *J*=29.3, 25.3 Hz), 121.0 (t, *J* = 246 Hz), 174.0;¹⁹F NMR (CDCl₃): δ -125 (dddd, *J*=256, 16.8, 12.2, 7.6 Hz), -118 (dddd, *J*=256, 16.8, 10.7, 4.6 Hz); IR (neat): v 3448, 1735, 1718 cm⁻¹.

4-(2-t-Butyldimethylsilyloxy-1, 1-difluoroethyl)-γ-butyrolactone (11)

To a solution of ethyl 6-*t*-butyldimethylsilyloxy-5,5-difluoro-4-hydroxyhexanoate (**10**) (324 mg, 1.0 mmol) in benzene (10 mL), a catalytic amount of pyridinium *p*-toluenesulfonate was added at 90 °C. After 20 h of stirring at 90 °C, the solvent was removed *in vacuo*. Oily materials were purified by column chromatography (silica gel, 20% AcOEt-hexane) to give 4-(2-*t*-butyldimethylsilyloxy-1,1-difluoroethyl)- γ -butyrolactone (**11**) (230 mg) in 82% yield.¹H NMR (CDCl₃): δ 0.98 (3 H, d, *J*=0.5 Hz), 0.10 (3 H, s), 0.90 (6H, s), 0.91 (3 H, s), 2.31-2.40 (1 H, m), 2.43-2.57 (2 H, m), 2.60-2.68 (1 H, m), 3.83 (1 H, dt, *J*=11.5, 6.4 Hz), 3.95 (1 H, ddd, *J*=25.9, 11.5, 4.6 Hz), 4.84 (1 H, dddd, *J*=21.2, 8.5, 4.6, 2.7 Hz);¹³C NMR (CDCl₃): δ -5.7, -3.7, 18.1, 20.2 (dd, *J*=3.8, 2.2 Hz), 25.6, 27.1 (d, *J*=1.6 Hz), 61.9 (dd, *J*=38.3, 26.4 Hz), 74.8 (dd, *J*=37.8, 24.9 Hz), 120.0 (t, *J*=245 Hz), 176.2;¹⁹F NMR (CDCl₃): δ -128 (ddt, *J*=263, 21.4, 4.6 Hz), -120 (dddd, *J*=263, 25.9, 12.2, 3.1 Hz); IR (neat): v 1794 cm⁻¹.

4-(2-t-Butyldimethylsilyloxy-1, 1-difluoroethyl)- α -methylene- γ -butyrolactone (1 2)

n-Butyllithium (1.6 M in hexane, 8.31 mL, 13.3 mmol) was added to a solution of diisopropylamine (1.86 mL, 13.3 mmol) in THF (40 mL) at -78 °C under an argom atmosphere. After 10 min of stirring, 4-(2-*t*-butyldimethylsilyloxy-1,1-difluoroethyl)- γ -butyrolactone (**1 1**)(2.88 g, 10.3 mmol) in tetrahydrofuran (40 mL) was added to the mixture at -78 °C. After 1 h of stirring, *N*,*N*-dimethylmethyleneammonium iodide (2.83 g, 15.3 mmol) was added and stirred for 1h. On removal of the solvent, the residue was diluted with methanol. To the mixture, methyl iodide (10 mL) was added, and the whole was stirred for

24 h. Aqueous 5% NaHCO₃ solution was added to the mixture, and the whole was vigurously stirred. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic extracts were dried over MgSO₄, and the solvent was removed *in vacuo*. Oily materials were purified by column chromatography (silica gel, 10% AcOEt-hexane) to give 4-(2-*t*-butyldimethyl-silyloxy-1,1-difluoroethyl)- α -methylene- γ -butyrolactone (**1 2**) (1.53 g) in 51% yield and starting material (**1 1**) (683 mg) was recovered in 24% yield.¹H NMR (CDCl₃): δ 0.10 (3 H, s), 0.11 (3 H, s), 0.90 (9 H, s), 3.05 (1 H, ddt, *J*=17.8, 9.0, 2.9 Hz), 3.16 (1 H, ddt, *J*=17.8, 4.9, 2.7 Hz), 3.85 (1 H, td, *J*=11.7, 6.6 Hz), 3.99 (1 H, ddd, *J*=25.9, 11.5, 4.6 Hz), 4.87 (1 H, dddd, *J*=20.0, 9.0, 4.9, 2.7 Hz), 5.73 (1 H, t,*J*=2.7 Hz), 6.30 (1 H, t, *J*=2.9 Hz);¹³C NMR (CDCl₃): δ -5.6, 18.2, 25.6, 26.1 (dd, *J*=4.4, 2.4 Hz), 61.8 (dd, *J*=38.1, 26.4 Hz), 71.8 (dd, *J*=38.3, 25.1 Hz), 119.7 (dd, *J*=246, 245 Hz), 123.2, 132.4, 169.1;¹⁹F NMR (CDCl₃): δ -129 (ddt, *J*=264, 19.8, 6.1 Hz), -120 (dddd, *J*=264, 25.9, 12.2, 3.1 Hz); IR (neat): v 1783, 1667 cm⁻¹.

4-(1,1-Difluoro-2-hydroxyethyl)- α -methylene- γ -butyrolactone (**1** 3)

To a solution of 4-(2-*t*-butyldimethylsilyloxy-1,1-difluoroethyl)- α -methylene- γ -butyrolactone (**1 2**) (800 mg, 2.74 mmol) in tetrahydrofuran (30 mL), tetrabutylammonium fluoride (1.0 M in tetrahydrofuran, 3.29 mL, 3.29 mmol) was added at 0 °C. After 10 min of stirring, the mixture was quenched with water. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic extracts were dried over MgSO₄. On removal of the solvent, oily materials were purified by column chromatography (silica gel, 50% AcOEt-hexane) to give 4-(1,1-difluoro-2-hydroxyethyl)- α -methylene- γ -butyrolactone (**1 3**) (428 mg) in 88% yield.¹H NMR (CDCl₃): δ 2.28 (1 H, t, *J*=6.8 Hz), 3.09 (1 H, ddt, *J*=17.8, 9.0, 2.9 Hz), 3.18 (1 H, ddt, *J*=17.8, 4.9, 2.7 Hz), 3.89-4.07 (2 H, m), 4.49 (1 H, dddd, *J*=20.5, 8.8, 4.6, 2.2 Hz), 5.77 (1 H, t, *J*=2.4 Hz), 6.32 (1 H, t, *J*=2.9 Hz);¹³C NMR (CDCl₃): δ 26.1 (dd, *J*=4.5, 2.3 Hz), 61.2 (dd, *J*=34.9, 26.0 Hz), 72.4 (dd, *J*=38.2, 25.1 Hz), 119.7 (dd, *J*=248, 243 Hz), 123.9, 132.1, 169.7;¹⁹F NMR (CDCl₃): δ -129 (ddt, *J*=266, 21.4, 7.6 Hz), -121 (dddd, *J*=266, 23.7, 13.7, 2.3 Hz);IR (neat):v 3442, 1776, 1666 cm⁻¹; HRMS calcd for C₇H₈O₃F₂ (M)+ 178.0441, found 178.0449.

REFERENCES

- (a) R. Filler and Y. Kobayashi, "Biomedicinal Aspects of Fluorine Chemistry," Kodansha Elsevier Biomedical, Tokyo, 1982. (b) J. T. Welch and S. Eswarakrishnan, "Fluorine in Bioorganic Chemistry," John Wiley & Sons, New York, 1991.
- 2. For a review, see. J. T. Welch, Tetrahedron, 1987, 43, 3123.
- (a) J. Kollonitsch, *Isr. J. Chem.*, 1987, **38**, 357. (b) P. Bey, F. Gerhart, V. V. Dorsselaer, and C. Danzin, *J. Med. Chem.*, 1983, **26**, 1551. (c) P. J. Casara, M. T. Kenny, and K. C. Jund, *Tetrahedron Lett.*, 1991, **32**, 3823. (d) S. Kaneko, T. Yamazaki, and T. Kitazume, *J. Org. Chem.*, 1993, **58**, 2302 and references cited therein.
- 4. T. Yamazaki, J. Haga, and T. Kitazume, *Bioorg. Med. Chem. Lett.*, 1991, 1, 271.
- 5. K. Murata, S. Kaneko, and T. Kitazume, *Bioorg. Med. Chem. Lett.*, 1993, 3, 2685.

Received, 7th February, 1997